6826 Stock Overview
Shanghai Haohai Biological Technology Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 6826 from our risk checks.
Shanghai Haohai Biological Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$28.30 |
| 52 Week High | HK$42.95 |
| 52 Week Low | HK$21.71 |
| Beta | 0.76 |
| 11 Month Change | -15.90% |
| 3 Month Change | -4.87% |
| 1 Year Change | -11.96% |
| 33 Year Change | -27.03% |
| 5 Year Change | -14.24% |
| Change since IPO | -32.16% |
Recent News & Updates
Recent updates
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease
Jul 25
Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All
May 22Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?
Feb 12Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 30Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price
May 08Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Apr 19Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Mar 04Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 03Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?
Jan 10Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Oct 08Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly
Jul 07Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%
May 27These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Apr 04Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%
Mar 16Shareholder Returns
| 6826 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -3.7% | 1.5% | 0.4% |
| 1Y | -12.0% | -11.2% | 12.0% |
Return vs Industry: 6826 matched the Hong Kong Biotechs industry which returned -11.2% over the past year.
Return vs Market: 6826 underperformed the Hong Kong Market which returned 12% over the past year.
Price Volatility
| 6826 volatility | |
|---|---|
| 6826 Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 6826 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6826's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,179 | Jianying Wu | www.3healthcare.com |
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. The company offers ophthalmology products consisting intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop.
Shanghai Haohai Biological Technology Co., Ltd. Fundamentals Summary
| 6826 fundamental statistics | |
|---|---|
| Market cap | HK$14.79b |
| Earnings (TTM) | HK$462.35m |
| Revenue (TTM) | HK$2.95b |
14.1x
P/E Ratio2.2x
P/S RatioIs 6826 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6826 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.75b |
| Cost of Revenue | CN¥848.86m |
| Gross Profit | CN¥1.90b |
| Other Expenses | CN¥1.47b |
| Earnings | CN¥430.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.87 |
| Gross Margin | 69.10% |
| Net Profit Margin | 15.66% |
| Debt/Equity Ratio | 7.0% |
How did 6826 perform over the long term?
See historical performance and comparison